Genomic Biomarkers for Breast Cancer Risk

Overview

Journal Adv Exp Med Biol

Specialties Biology
General Medicine

Date 2016 Mar 19

PMID 26987529

Citations 25

Authors

Michael F Walsh

Katherine L Nathanson

Fergus J Couch

Kenneth Offit

Affiliations

Soon will be listed here.

Abstract

Clinical risk assessment for cancer predisposition includes a three-generation pedigree and physical examination to identify inherited syndromes. Additionally genetic and genomic biomarkers may identify individuals with a constitutional basis for their disease that may not be evident clinically. Genomic biomarker testing may detect molecular variations in single genes, panels of genes, or entire genomes. The strength of evidence for the association of a genomic biomarker with disease risk may be weak or strong. The factors contributing to clinical validity and utility of genomic biomarkers include functional laboratory analyses and genetic epidemiologic evidence. Genomic biomarkers may be further classified as low, moderate or highly penetrant based on the likelihood of disease. Genomic biomarkers for breast cancer are comprised of rare highly penetrant mutations of genes such as BRCA1 or BRCA2, moderately penetrant mutations of genes such as CHEK2, as well as more common genomic variants, including single nucleotide polymorphisms, associated with modest effect sizes. When applied in the context of appropriate counseling and interpretation, identification of genomic biomarkers of inherited risk for breast cancer may decrease morbidity and mortality, allow for definitive prevention through assisted reproduction, and serve as a guide to targeted therapy .

Citing Articles

Metabolomics-Driven Biomarker Discovery for Breast Cancer Prognosis and Diagnosis.

Kaur R, Gupta S, Kulshrestha S, Khandelwal V, Pandey S, Kumar A Cells. 2025; 14(1.

PMID: 39791706 PMC: 11720085. DOI: 10.3390/cells14010005.

Nutritional Genomics and Cancer Prevention.

Aslam S, Iqbal R, Saeed R, Akram N, Ijaz F, Liaqat I Cancer Treat Res. 2024; 191:217-244.

PMID: 39133410 DOI: 10.1007/978-3-031-55622-7_9.

Nucleolar Localization of the RNA Helicase DDX21 Predicts Survival Outcomes in Gynecologic Cancers.

Aljardali M, Kremer K, Parker J, Fleming E, Chen H, Lea J Cancer Res Commun. 2024; 4(6):1495-1504.

PMID: 38767454 PMC: 11172406. DOI: 10.1158/2767-9764.CRC-24-0001.

Copper Chaperone for Superoxide Dismutase Subtypes as a Prognostic Marker in Luminal B Breast Cancer.

Li Y, Du W, Yang R, Wei X, Li H, Zhang X Clin Med Insights Oncol. 2024; 18:11795549231219239.

PMID: 38187458 PMC: 10771053. DOI: 10.1177/11795549231219239.

Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment.

Swaminathan H, Saravanamurali K, Yadav S Med Oncol. 2023; 40(8):238.

PMID: 37442848 DOI: 10.1007/s12032-023-02111-9.

References

Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A . PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007; 39(2):165-7. PMC: 2871593. DOI: 10.1038/ng1959. View

Lord C, Ashworth A . Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med. 2013; 19(11):1381-8. DOI: 10.1038/nm.3369. View

Antoniou A, Kartsonaki C, Sinilnikova O, Soucy P, McGuffog L, Healey S . Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet. 2011; 20(16):3304-21. PMC: 3652640. DOI: 10.1093/hmg/ddr226. View

Gold B, Kirchhoff T, Stefanov S, Lautenberger J, Viale A, Garber J . Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A. 2008; 105(11):4340-5. PMC: 2393811. DOI: 10.1073/pnas.0800441105. View

Foulkes W, Ghadirian P, Akbari M, Hamel N, Giroux S, Sabbaghian N . Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res. 2007; 9(6):R83. PMC: 2246183. DOI: 10.1186/bcr1828. View

Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D . Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010; 42(5):410-4. DOI: 10.1038/ng.569. View

Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H . Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 2011; 12(6):559-67. DOI: 10.1016/S1470-2045(11)70119-X. View

Claus E, Risch N, Thompson W . The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat. 1993; 28(2):115-20. DOI: 10.1007/BF00666424. View

Metcalfe K, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P . International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2008; 122(9):2017-22. PMC: 2936778. DOI: 10.1002/ijc.23340. View

10.

Eisen A, Lubinski J, Klijn J, Moller P, Lynch H, Offit K . Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005; 23(30):7491-6. DOI: 10.1200/JCO.2004.00.7138. View

11.

Kauff N, Satagopan J, Robson M, Scheuer L, Hensley M, Hudis C . Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002; 346(21):1609-15. DOI: 10.1056/NEJMoa020119. View

12.

Morris E, Liberman L, Ballon D, Robson M, Abramson A, Heerdt A . MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol. 2003; 181(3):619-26. DOI: 10.2214/ajr.181.3.1810619. View

13.

Marsh D, Kum J, Lunetta K, Bennett M, GORLIN R, Ahmed S . PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet. 1999; 8(8):1461-72. DOI: 10.1093/hmg/8.8.1461. View

14.

Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S . BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell. 2011; 20(6):797-809. DOI: 10.1016/j.ccr.2011.11.014. View

15.

Hermsen B, Olivier R, Verheijen R, van Beurden M, de Hullu J, Massuger L . No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer. 2007; 96(9):1335-42. PMC: 2360170. DOI: 10.1038/sj.bjc.6603725. View

16.

Veronesi U, Maisonneuve P, Costa A, Sacchini V, MALTONI C, Robertson C . Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998; 352(9122):93-7. DOI: 10.1016/s0140-6736(98)85011-3. View

17.

Maxwell K, Nathanson K . Common breast cancer risk variants in the post-COGS era: a comprehensive review. Breast Cancer Res. 2013; 15(6):212. PMC: 3978855. DOI: 10.1186/bcr3591. View

18.

Rebbeck T, Mitra N, Domchek S, Wan F, Friebel T, Tran T . Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res. 2011; 71(17):5792-805. PMC: 3170727. DOI: 10.1158/0008-5472.CAN-11-0773. View

19.

Lynch H, KRUSH A . Genetic predictability in breast cancer risk. Surgical implications. Arch Surg. 1971; 103(1):84-8. DOI: 10.1001/archsurg.1971.01350070110027. View

20.

Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P . E-cadherin germline mutations in familial gastric cancer. Nature. 1998; 392(6674):402-5. DOI: 10.1038/32918. View